Mesenchymal stem cell, method for clonogenic expansion thereof, method for isolating thereof, and use thereof

Abstract

A mesenchymal stem cell is provided. The mesenchymal stem cell that expresses an insulin-like growth factor 1 receptor have been cultured in media containing human cord blood serum and isolated, such that an insulin-like growth factor 1 receptor expression is enhanced in the isolated mesenchymal stem cells.

What is claimed is: 
     
         1 . A mesenchymal stem cell, which has been cultured in media containing human cord blood serum to enhance an insulin-like growth factor 1 receptor expression of the mesenchymal stem cell and isolated, wherein the isolated mesenchymal stem cell expresses an insulin-like growth factor 1 receptor. 
     
     
         2 . The mesenchymal stem cell of  claim 1 , wherein the isolated mesenchymal stem cell is pluripotent. 
     
     
         3 . The mesenchymal stem cell of  claim 1 , wherein the isolated mesenchymal stem cell is a human cell. 
     
     
         4 . The mesenchymal stem cell of  claim 1 , wherein the isolated mesenchymal stem cell is an umbilical cord mesenchymal stem cell. 
     
     
         5 . A method for a clonogenic expansion of mesenchymal stem cell, the method comprising:
 culturing a plurality of mesenchymal stem cells expressing insulin-like growth factor 1 receptors in media containing human cord blood serum; and   isolating the mesenchymal stem cells that express the insulin-like growth factor 1 receptors.   
     
     
         6 . The method of  claim 5 , wherein a concentration of the human cord blood serum in the media is 1-10% (v/v). 
     
     
         7 . The method of  claim 5 , wherein the concentration of the human cord blood serum in the media is 2% (v/v). 
     
     
         8 . A method for obtaining a plurality of pluripotent mesenchymal stem cells, the method comprising:
 providing a cell mixture from a mammalian tissue; and   isolating a plurality of cells that express insulin-like growth factor 1 receptors from the cell mixture to obtain the pluripotent mesenchymal stem cells.   
     
     
         9 . The method of  claim 8 , wherein isolating the cells further comprises isolating from the cell mixture cells expressing interleukin 22 receptors alpha 1. 
     
     
         10 . The method of  claim 8 , wherein the mammalian tissue is selected from the group consisting of a bone marrow, a dental pulp, a placenta, an umbilical cord, an adipose tissue, and a combination thereof. 
     
     
         11 . A method for treating an ischemic heart disease, the method comprising administering a composition containing a plurality of mesenchymal stem cells to a subject in need for a treatment of the ischemic heart disease, wherein the mesenchymal stem cell expresses an insulin-like growth factor 1 receptor. 
     
     
         12 . The method of  claim 11 , wherein the ischemic heart disease is a myocardium infarction. 
     
     
         13 . The method of  claim 12 , wherein the composition reduces a fibrosis resulting from the myocardium infarction. 
     
     
         14 . The method of  claim 12 , wherein the composition reduces an inflammatory effect on the myocardium infarction. 
     
     
         15 . A method for treating a brain tissue damage, the method comprising administering a composition containing a plurality of mesenchymal stem cells to a subject in need for a treatment of the brain tissue damage, wherein the mesenchymal stem cell expresses an insulin-like growth factor 1 receptor. 
     
     
         16 . The method of  claim 15 , wherein the brain tissue damage results from a cerebral ischemic disease. 
     
     
         17 . The method of  claim 16 , wherein the cerebral ischemic disease is a stroke. 
     
     
         18 . The method of  claim 15 , wherein the brain tissue damage results from a neural degenerative disease. 
     
     
         19 . The method of  claim 18 , wherein the brain tissue damage resulting from the neural degenerative disease is a Parkinson's disease. 
     
     
         20 . The method of  claim 15 , wherein the composition comprises an ingredient increasing a glucose metabolic activity of the subject, enhancing an angiogenesis of the subject, or augmenting a neurite regeneration of the subject.